South Korea · Health Care · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-37.05%
2025 (actual)
ROA
-19.57%
2025 (actual)
Gross Margin
82.62%
2025 (actual)
Net Margin
-41.87%
2025 (actual)
Total Assets
₩83,482.86M
2025 (actual)
Net Income
-₩16,296.85M
2025 (actual)
Valuation
₩289,670.81M
2026 (forecast)
Stock Price
₩12,960
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+27.4 pt
Company
ROA
+16.2 pt
Company
Gross Margin
-5.1 pt
Company
Sector average
Net Margin
+33.4 pt
Company
Total Assets
+112.9%
Company
Sector average
Net Income
+64.3%
Company
Valuation
+100.3%
Company
Sector average
Stock Price
+100.3%
Company
Sector average
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for L&K Biomed Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.